Kapitalradar

Swiss capital increases, read from the official gazette and scored for financing rounds.

updated every weekdayrelease r10data as of 8 Oct 2026

↺ Try a rewind: Soverli AG on 24 Sep 2025, 83 days before the round was announced
Latest available record · 8 Oct 2026

Release evaluation · 7 Oct 2026 · does not rewind · rules + Claude: precision 2%–100% (n=17), recall 16/30 announced rounds · rules-only: precision 1%–99% (n=29), recall 18/30 announced rounds · Methodology

Published by 5 Apr 2026
Drag the red line through time · ← → a day · Shift+← → a week. Later days aren’t drawn: they haven’t been published yet.
1733not yet publishedAug 25Sep 25Oct 25Nov 25Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26

Scope · likely financings by canton

40 likely financings · 7 Mar 2026 – 5 Apr 2026 · the feed below shows one weekClick a canton to filter the feedMap: Natural Earth

Likely financing
Looks like new money from outside investors: Claude, reading the entry and the rule signals, scores it 0.60 or higher.
Undecided
Some financing signals, not enough to call it: a score from 0.35 to below 0.60, or no usable score.
Capital increased
No sign of a financing round: the pre-filter found nothing to send to Claude, or Claude scored it below 0.35. Typical causes are converted loans, assets contributed in kind, reserves turned into capital or a conversion to an AG.
Confirmed round
A financing announcement on startupticker.ch names the company and matches this increase.

Published 30 Mar – 5 Apr 2026

45 capital increases · 8 shown
Showing: likely financings and confirmed rounds ▾
Show
Capital increases published 30 Mar – 5 Apr 2026
CompanyStatusNominal share capital (CHF)
before → after		New shares, % of
post-step shares		Announced roundnot disclosed in the SHABSHAB publishedSource
APTISSEN SAGE · étude, fabrication, commercialisation de produits biomédicaux ainsi que gestion de brevets et licences (cf. …SHAB publication HR02-1006614353Likely financingscore 0.702’970’000 → 3’365’858.43New shares 11.2%11.2%—1 Apr 2026SHAB publication HR02-1006614353
MoonRise Bio AGZG · Die Gesellschaft bezweckt die Entwicklung präklinischer Biologika in den Bereichen der Immunologie und …SHAB publication HR02-1006613596Likely financingscore 0.80100’000 → 117’647.06New shares 15.0%15.0%—1 Apr 2026SHAB publication HR02-1006613596
MediCrops AGSZ · Die Gesellschaft bezweckt die Erforschung, Entwicklung, Herstellung, Handel, Import, Export, Vermarktung, …SHAB publication HR02-1006613520Likely financingscore 0.62179’011.17 → 193’585.67New shares 7.5%7.5%—1 Apr 2026SHAB publication HR02-1006613520
Alpha Mobility SAVD · la Société a pour but la prestation de service, de conseil et d'assistance dans les domaines de la direction …SHAB publication HR02-1006611110Likely financingscore 0.72105’623.54 → 148’716.34New shares 29.0%29.0%—30 Mar 2026SHAB publication HR02-1006611110
Tosoo AGZH · Die Gesellschaft bezweckt die Entwicklung, Herstellung und Vermarktung von Technologie zur Förderung der …SHAB publication HR02-1006610309Likely financingscore 0.93125’000 → 162’561New shares 23.1%23.1%—30 Mar 2026SHAB publication HR02-1006610309
Lobby AGZH · Die Gesellschaft bezweckt die Entwicklung, die Vermarktung und den Vertrieb von IT-Systemen und …SHAB publication HR02-1006610092Confirmed roundscore 0.93Announced round: USD 2’200’000 ↗100’000 → 131’349.60New shares 23.9%23.9%USD 2’200’000 ↗30 Mar 2026SHAB publication HR02-1006610092
Jurata AGZH · Die Gesellschaft bezweckt die Erstellung und den Vertrieb von Software sowie die Erbringung von …SHAB publication HR02-1006610047Likely financingscore 0.80100’000 → 128’345.65New shares — nominal value per share changed— nominal value per share changed—30 Mar 2026SHAB publication HR02-1006610047
ALP Bio AGZH · Der Zweck der Gesellschaft ist die Forschung, Entwicklung, Kommer-zialisierung und Bereitstellung von …SHAB publication HR02-1006609939Likely financingscore 0.96100’000 → 131’096.20New shares 23.7%23.7%—30 Mar 2026SHAB publication HR02-1006609939

37 other capital increases published this week ▸